Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

Journal of Clinical Oncology

Volumn 20, Issue 21, 2002, Pages 4368-4380

  Dvorak, Harold F ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

BLOOD VESSEL PERMEABILITY; CANCER THERAPY; CELL SURVIVAL; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR DIAGNOSIS;

CAPILLARY PERMEABILITY; CELL DIVISION; CELL MOVEMENT; CLINICAL TRIALS; ENDOTHELIAL GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROTEIN ISOFORMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036842215     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.10.088     Document Type: Review

References (214)

1. Dvorak HF, Orenstein NS, Carvalho AC, et al: Induction of a fibrin-gel investment: An early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol 122:166-174, 1979
2. Brown LF, Detmar M, Claffey K, et al: Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine. EXS 79:233-269, 1997
3. Dvorak HF, Brown LF, Detmar M, et al: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039, 1995
4. Stiver S, Dvorak H: Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF). J Clin Ligand Assay 23:193-205, 2000
5. Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527-543, 1999
6. Carmeliet P, Ferreira V, Breier G, et al: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-439, 1996
7. Ferrara N, Carver-Moore K, Chen H, et al: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442, 1996
8. Dvorak HF, Dvorak AM, Manseau EJ, et al: Fibrin gel investment associated with line I and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs: Role of cellular immunity, myofibroblasts microvascular damage, and infarction in line 1 tumor regression. J Natl Cancer Inst 62:1459-1472, 1979
9. Senger DR, Galli SJ, Dvorak AM, et al: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985, 1983
10. Dvorak HF, Nagy JA, Dvorak AM: Structure of solid tumors and their vasculature: Implications for therapy with monoclonal antibodies. Cancer Cells 3:77-85, 1991
11. Joukov V, Pajusola K, Kaipainen A, et al: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:290-298, 1996
12. Valtola R, Salven P, Heikkila P, et al: VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154:1381-1390, 1999
13. Jeltsch M, Kaipainen A, Joukov V, et al: Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276:1423-1425, 1997
14. Soker S, Takashima S, Miao HQ, et al: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735-745, 1998
15. Matsumoto T, Claesson-Welsh L: VEGF receptor signal transduction. Sci STKE 112:RE21, 2001
16. Carmeliet P, Moons L, Luttun A, et al: Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7:575-583, 2001
17. DiSalvo J, Bayne ML, Conn G, et al: Purification and characterization of a naturally occurring vascular endothelial growth factor: Placenta growth factor heterodimer. J Biol Chem 270:7717-7723, 1995
18. Olofsson B, Pajusola K, Kaipainen A, et al: Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A 93:2576-2581, 1996
19. Joukov V, Kaipainen A, Jeltsch M, et al: Vascular endothelial growth factors VEGF-B and VEGF-C. J Cell Physiol 173:211-215, 1997
20. Meyer M, Clauss M, Lepple-Wienhues A, et al: A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signaling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 18:363-374, 1999
21. Anderson KC: Multiple myeloma: Advances in disease biology - Therapeutic implications. Semin Hematol 38:6-10, 2001
22. Aoki Y, Tosato G: Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomas. Leuk Lymphoma 41:229-237, 2001
23. Bellamy WT, Richter L, Frutiger Y, et al: Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 59:728-733, 1999
24. Chen H, Treweeke AT, West DC, et al: In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 96:3181-3187, 2000
25. Foss HD, Araujo I, Demel G, et al: Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol 183:44-50, 1997
26. Hussong JW, Rodgers GM, Shami PJ: Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95:309-313, 2000
27. Kini AR, Peterson LA, Tallman MS, et al: Angiogenesis in acute promyelocytic leukemia: Induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood 97:3919-3924, 2001
28. Brown LF, Berse B, Jackman RW, et al: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86-91, 1995
29. Guidi AJ, Abu-Jawdeh G, Berse B, et al: Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 87:1237-1245, 1995
30. Wong MP, Cheung N, Yuen ST, et al: Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression. Int J Cancer 81:845-850, 1999
31. Berkman RA, Merrill MJ, Reinhold WC, et al: Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91:153-159, 1993
32. Brown LF, Tognazzi K, Dvorak HF, et al: Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 148:1065-1074, 1996
33. Harrison-Woolrych ML, Sharkey AM, Charnock-Jones DS, et al: Localization and quantification of vascular endothelial growth factor messenger ribonucleic acid in human myometrium and leiomyomata. J Clin Endocrinol Metab 80:1853-1858, 1995
34. Hlatky L, Tsionou C, Hahnfeldt P, et al: Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. Cancer Res 54:6083-6086, 1994
35. Detmar M, Brown LF, Berse B, et al: Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. J Invest Dermatol 108:263-268, 1997
36. Fukumura D, Xavier R, Sugiura T, et al: Tumor induction of VEGF promoter activity in stromal cells. Cell 94:715-725, 1998
37. Muller YA, Li B, Christinger HW, et al: Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci U S A 94:7192-7197, 1997
38. Claffey KP, Senger DR, Spiegelman BM: Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF. Biochim Biophys Acta 1246:1-9, 1995
39. Tischer E, Mitchell R, Hartman T, et al: The human gene for vascular endothelial growth factor: Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947-11954, 1991
40. Lin R, LeCouter J, Kowalski J, et al: Characterization of endocrine gland-derived vascular endothelial growth factor signaling in adrenal cortex capillary endothelial cells. J Biol Chem 277:8724-8729, 2002
41. 2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50:1774-1778, 1990
42. Houck KA, Leung DW, Rowland AM, et al: Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267:26031-26037, 1992
43. Bergers G, Brekken R, McMahon G, et al: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737-744, 2000
44. Senger D, Van De Water L, Brown L, et al: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12:303-324, 1993
45. de Vries C, Escobedo JA, Ueno H, et al: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991, 1992
46. Terman BI, Carrion ME, Kovacs E, et al: Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6:1677-1683, 1991
47. Kendall RL, Thomas KA: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 90:10705-10709, 1993
48. Kendall RL, Wang G, Thomas KA: Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226:324-328, 1996
49. Fong GH, Rossant J, Gertsenstein M, et al: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66-70, 1995
50. Shalaby F, Rossant J, Yamaguchi TP, et al: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62-66, 1995
51. Miao HQ, Klagsbrun M: Neuropilin is a mediator of angiogenesis. Cancer Metastasis Rev 19:29-37, 2000
52. Miao HQ, Lee P, Lin H, et al: Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 14:2532-2539, 2000
53. Zeng H, Dvorak HF, Mukhopadhyay D: Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) receptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem 276:26969-26979, 2001
54. Clauss M, Weich H, Breier G, et al: The vascular endothelial growth factor receptor Flt-1 mediates biological activities: Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 271:17629-17634, 1996
55. Gille H, Kowalski J, Li B, et al: Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2): A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 276:3222-3230, 2001
56. Bussolati B, Dunk C, Grohman M, et al: Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol 159:993-1008, 2001
57. Dvorak HF, Nagy JA, Feng D, et al: Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 237:97-132, 1999
58. Joukov V, Kumar V, Sorsa T, et al: A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem 273:6599-6602, 1998
59. Kadambi A, Carreira CM, Yun CO, et al: Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: Role of VEGF-receptor 2 and host VEGF-A, Cancer Res 61:2404-2408, 2001
60. Dvorak HF: Tumors: Wounds that do not heal - Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650-1655, 1986
61. Dvorak HF, Van DeWater L, Bitzer AM, et al: Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res 43:4434-4442, 1983
62. Dvorak HF, Senger DS, Dvorak AM, et al: Regulation of extravascular coagulation by microvascular permeability. Science 227:1059-1061, 1985
63. Dvorak HF, Harvey VS, Estrella P, et al: Fibrin containing gels induce angiogenesis: Implications for tumor stroma generation and wound healing. Lab Invest 57:673-686, 1987
64. Boucher Y, Jain RK: Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: Implications for vascular collapse. Cancer Res 52:5110-5114, 1992
65. Boucher Y, Salehi H, Witwer B, et al: Interstitial fluid pressure in intracranial turnouts in patients and in rodents. Br J Cancer 75:829-836, 1997
66. Criscuolo GR: The genesis of peritumoral vasogenic brain edema and tumor cysts: A hypothetical role for tumor-derived vascular permeability factor. Yale J Biol Med 66:277-314, 1993
67. Olson TA, Mohanraj D, Carson LF, et al: Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 54:276-280, 1994
68. Yeo KT, Wang HH, Nagy JA, et al: Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res 53:2912-2918, 1993
69. Kohn S, Nagy JA, Dvorak HF, et al: Pathways of macromolecular tracer transport across venules and small veins: Structural basis for the hyperpermeability of tumor blood vessels. Lab Invest 67:596-607, 1992
70. Dvorak AM, Kohn S, Morgan ES, et al: The vesiculo-vacuolar organelle (VVO): A distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J Leukoc Biol 59:100-115, 1996
71. Feng D, Nagy J, Hipp J, et al: Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med 183:1981-1986, 1996
72. Pettersson A, Nagy JA, Brown LF, et al: Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 80:99-115, 2000
73. Feng D, Nagy JA, Hipp J, et al: Reinterpretation of endothelial cell gaps induced by vasoactive mediators in guinea-pig, mouse and rat: Many are transcellular pores. J Physiol 504:747-761, 1997
74. Feng D, Nagy JA, Pyne K, et al: Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation 6:23-44, 1999
75. Feng D, Nagy JA, Dvorak AM, et al: Different pathways of macromolecule extravasation from hyperpermeable tumor vessels. Microvasc Res 59:24-37, 2000
76. Roberts WG, Palade GE: Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 108:2369-2379, 1995
77. McDonald DM, Thurston G, Baluk P: Endothelial gaps as sites for plasma leakage in inflammation. Microcirculation 6:7-22, 1999
78. Garcia-Cardena G, Folkman J: Is there a role for nitric oxide in tumor angiogenesis? J Natl Cancer Inst 90:560-561, 1998
79. Benjamin LE, Golijanin D, Itin A, et al: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159-165, 1999
80. Watanabe Y, Lee SW, Detmar M, et al: Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Oncogene 14:2025-2032, 1997
81. Brown LF, Berse B, Jackman RW, et al: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143:1255-1262, 1993
82. Brown LF, Berse B, Jackman RW, et al: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53:4727-4735, 1993
83. Hatva E, Kaipainen A, Mentula P, et al: Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am J Pathol 146:368-378, 1995
84. Hatva E, Bohling T, Jaaskelainen J, et al: Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol 148:763-775, 1996
85. Plate KH, Breier G, Millauer B, et al: Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53:5822-5827, 1993
86. Plate KH, Risau W: Angiogenesis in malignant gliomas. Glia 15:339-347, 1995
87. Wizigmann-Voos S, Breier G, Risau W, et al: Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 55:1358-1364, 1995
88. Detmar M, Brown LF, Schon MP, et al: Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 111:1-6, 1998
89. Clauss M, Gerlach M, Gerlach H, et al: Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172:1535-1545, 1990
90. Brown LF, Detmar M, Tognazzi K, et al: Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor. Lab Invest 76:245-255, 1997
91. Herold-Mende C, Steiner HH, Andl T, et al: Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab Invest 79:1573-1582, 1999
92. Robinson GS, Ju M, Shih SC, et al: Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development. FASEB J 15:1215-1217, 2001
93. Feng D, Nagy JA, Brekken RA, et al: Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors. J Histochem Cytochem 48:545-556, 2000
94. Nagy J, Vasile E, Brown L, et al: Vascular permeability factor/vascular endothelial growth factor-A (VPF/VEGF, VEGF-A) induces lymphangiogenesis as well as angiogenesis. FASEB J 16:A367, 2002 (abstr)
95. Soker S, Kaefer M, Johnson M, et al: Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol 159:651-659, 2001
96. Bachelder RE, Crago A, Chung J, et al: Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 61:5736-5740, 2001
97. Dvorak HF, Sioussat TM, Brown LF, et al: Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels. J Exp Med 174:1275-1278, 1991
98. Plate KH, Breier G, Weich HA, et al: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845-848, 1992
99. Qu H, Nagy JA, Senger DR, et al: Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium. J Histochem Cytochem 43:381-389, 1995
100. Eriksson U, Alitalo K: Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol 237:41-57, 1999
101. Claffey KP, Robinson GS: Regulation of VEGF/VPF expression in tumor cells: Consequences for tumor growth and metastasis. Cancer Metastasis Rev 15:165-176, 1996
102. Shih SC, Claffey KP: Hypoxia-mediated regulation of gene expression in mammalian cells. Int J Exp Pathol 79:347-357, 1998
103. Levy AP, Levy NS, Wegner S, et al: Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 270:13333-13340, 1995
104. Forsythe JA, Jiang BH, Iyer NV, et al: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-4613, 1996
105. Gerber HP, Condorelli F, Park J, et al: Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes: Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 272:23659-23667, 1997
106. Jain RK: Transport of molecules in the tumor interstitium: A review. Cancer Res 47:3039-3051, 1987
107. Mukhopadhyay D, Tsiokas L, Zhou XM, et al: Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375:577-581, 1995
108. Rak J, Mitsuhashi Y, Bayko L, et al: Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res 55:4575-4580, 1995
109. Rak J, Filmus J, Finkenzeller G, et al: Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 14:263-277, 1995
110. Rak J, Kerbel RS: Ras regulation of vascular endothelial growth factor and angiogenesis. Methods Enzymol 333:267-283, 2001
111. Ohh M, Kaelin WG Jr: The von Hippel-Lindau tumour suppressor protein: New perspectives. Mol Med Today 5:257-263, 1999
112. Clifford SC, Maher ER: Von Hippel-Lindau disease: Clinical and molecular perspectives. Adv Cancer Res 82:85-105, 2001
113. Pal S, Claffey KP, Dvorak HF, et al: The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem 272:27509-27512, 1997
114. Siemeister G, Weindel K, Mohrs K, et al: Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 56:2299-2301, 1996
115. Mukhopadhyay D, Tsiokas L, Sukhatme VP: Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 55:6161-6165, 1995
116. Pal S, Datta K, Mukhopadhyay D: Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 61:6952-6957, 2001
117. Zhang L, Yu D, Hu M, et al: Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 60:3655-3661, 2000
118. Claffey KP, Abrams K, Shih SC, et al: Fibroblast growth factor 2 activation of stromal cell vascular endothelial growth factor expression and angiogenesis. Lab Invest 81:61-75, 2001
119. Wojta J, Kaun C, Breuss JM, et al: Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Lab Invest 79:427-438, 1999
120. Stavri GT, Zachary IC, Baskerville PA, et al: Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells: Synergistic interaction with hypoxia. Circulation 92:11-14, 1995
121. Derynck R, Goeddel DV, Ullrich A, et al: Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 47:707-712, 1987
122. Slaton JW, Inoue K, Perrotte P, et al: Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 158:735-743, 2001
123. Berse B, Brown LF, Van de Water L, et al: Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3:211-220, 1992
124. Cullinan-Bove K, Koos RD: Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: Rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology 133:829-837, 1993
125. Garrido C, Saule S, Gospodarowicz D: Transcriptional regulation of vascular endothelial growth factor gene expression in ovarian bovine granulosa cells. Growth Factors 8:109-117, 1993
126. Adams J, Carder PJ, Downey S, et al: Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 60:2898-2905, 2000
127. Sato K, Yamazaki K, Shizume K, et al: Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J Clin Invest 96:1295-1302, 1995
128. Soh EY, Sobhi SA, Wong MG, et al: Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. Surgery 120:944-947, 1996
129. Tsopanoglou NE, Maragoudakis ME: On the mechanism of thrombin-induced angiogenesis. J Biol Chem 34:23969-23976, 1999
130. Kronemann N, Bouloumi A, Bassus S, et al: Aggregating human platelets stimulate expression of vascular endothelial growth factor in cultured vascular smooth muscle cells through a synergistic effect of transforming growth factor-beta(1) and platelet-derived growth factor(AB). Circulation 100:855-860, 1999
131. Li J, Hampton T, Morgan JP, et al: Stretch-induced VEGF expression in the heart. J Clin Invest 100:18-24, 1997
132. Gruden G, Thomas S, Burt D, et al: Mechanical stretch induces vascular permeability factor in human mesangial cells: Mechanisms of signal transduction. Proc Natl Acad Sci U S A 94:12112-12116, 1997
133. Chen KD, Li YS, Kim M, et al: Mechanotransduction in response to shear stress: Roles of receptor tryosine kinases, integrins, and Shc. J Biol Chem 274:18393-18400, 1999
134. Fukumura D, Xu L, Chen Y, et al: Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 61:6020-6024, 2001
135. Hu YL, Tee MK, Goetzl EJ, et al: Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 93:762-768, 2001
136. Gu JW, Brady AL, Anand V, et al: Adenosine upregulates VEGF expression in cultured myocardial vascular smooth muscle cells. Am J Physiol 277:H595-H602, 1999
137. Nauck M, Karakiulakis G, Perruchoud AP, et al: Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 341:309-315, 1998
138. Nagy JA, Morgan ES, Herzberg KT, et al: Pathogenesis of ascites tumor growth: Angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res 55:376-385, 1995
139. Sundberg C, Nagy JA, Brown LF, et al: Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am J Pathol 158:1145-1160, 2001
140. Tabone MD, Landman-Parker J, Arcil B, et al: Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors? Clin Cancer Res 7:538-543, 2001
141. Mineta H, Miura K, Ogino T, et al: Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br J Cancer 83:775-781, 2000
142. Inoue K, Slaton JW, Karashima T, et al: The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 6:4866-4873, 2000
143. Shih CH, Ozawa S, Ando N, et al: Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 6:1161-1168, 2000
144. Kaya M, Wada T, Akatsuka T, et al: Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6:572-577, 2000
145. Heffelfinger SC, Miller MA, Yassin R, et al: Angiogenic growth factors in preinvasive breast disease. Clin Cancer Res 5:2867-2876, 1999
146. Borre M, Nerstrom B, Overgaard J: Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 6:1882-1890, 2000
147. Kuniyasu H, Troncoso P, Johnston D, et al: Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 6:2295-2308, 2000
148. Linderholm B, Tavelin B, Grankvist K, et al: Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer? Br J Cancer 81:727-732, 1999
149. Foekens JA, Peters HA, Grebenchtchikov N, et al: High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61:5407-5414, 2001
150. Cascinu S, Staccioli MP, Gasparini G, et al: Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 6:2803-2807, 2000
151. Callagy G, Dimitriadis E, Harmey J, et al: Immunohistochemical measurement of tumor vascular endothelial growth factor in breast cancer: A more reliable predictor of tumor stage than microvessel density or serum vascular endothelial growth factor. Appl Immunohistochem Molecul Morphol 8:104-109, 2000
152. Shen GH, Ghazizadeh M, Kawanami O, et al: Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 83:196-203, 2000
153. Sato F, Shimada Y, Watanabe G, et al: Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer. Br J Cancer 80:1366-1372, 1999
154. Loncaster JA, Cooper RA, Logue JP, et al: Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 83:620-625, 2000
155. Yudoh K, Kanamori M, Ohmori K, et al: Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 84:1610-1615, 2001
156. Abdulrauf SI, Edvardsen K, Ho KL, et al: Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 88:513-520, 1998
157. Toi M, Hoshina S, Takayanagi T, et al: Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 85:1045-1049, 1994
158. Fuhrmann-Benzakein E, Ma MN, Rubbia-Brandt L, et al: Elevated levels of angiogenic cytokines in the plasma of cancer patients. Int J Cancer 85:40-45, 2000
159. Kraft A, Weindel K, Ochs A, et al: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85:178-187, 1999
160. Salven P, Manpaa H, Orpana A, et al: Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 3:647-651, 1997
161. Chin KF, Greenman J, Gardiner E, et al: Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer 83:1425-1431, 2000
162. Davies MM, Jonas SK, Kaur S, et al: Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver metastasis vascularity and volume. Br J Cancer 82:1004-1008, 2000
163. George ML, Eccles SA, Tutton MG, et al: Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: Clinical evidence of platelet scavenging? Clin Cancer Res 6:3147-3152, 2000
164. Hefler L, Tempfer C, Obermair A, et al: Serum concentrations of vascular endothelial growth factor in vulvar cancer. Clin Cancer Res 5:2806-2809, 1999
165. Salven P, Teerenhovi L, Joensuu H: A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 90:3167-3172, 1997
166. Salven P, Orpana A, Joensuu H: Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 5:487-491, 1999
167. Banks RE, Forbes MA, Kinsey SE, et al: Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology. Br J Cancer 77:956-964, 1998
168. Gunsilius E, Petzer AL, Gastl G: Correspondence re: P. Salven et al: Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor - Clin Cancer Res 5:487-91, 1999. Clin Cancer Res 5:2978-2979, 1999 (letter)
169. Kondo S, Asano M, Matsuo K, et al: Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1221:211-214, 1994
170. Brown LF, Olbricht SM, Berse B, et al: Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions. J Immunol 154:2801-2807, 1995
171. Wartiovaara U, Salven P, Mikkola H, et al: Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 80:171-175, 1998
172. Mohle R, Green D, Moore MA, et al: Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 94:663-668, 1997
173. Freeman MR, Schneck FX, Gagnon ML, et al: Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis. Cancer Res 55:4140-4145, 1995
174. Jelkmann W: Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 47:617-623, 2001
175. Zebrowski BK, Yano S, Liu W, et al: Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 5:3364-3368, 1999
176. Zebrowski BK, Liu W, Ramirez K, et al: Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6:373-378, 1999
177. Hazelton D, Nicosia RF, Nicosia SV: Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res 5:823-829, 1999
178. Jones A, Crew J: Vascular endothelial growth factor and its correlation with superficial bladder cancer recurrence rates and stage progression. Urol Clin North Am 27:191-197, 2000
179. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186, 1971
180. Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13:31-36, 1991
181. Folkman J: Angiogenesis and angiogenesis inhibition: An overview. EXS 79:1-8, 1997
182. O'Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328, 1994
183. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997
184. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993
185. Schlaeppi JM, Wood JM: Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Rev 18:473-481, 1999
186. Klement G, Baruchel S, Rak J, et al: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-R24, 2000
187. Browder T, Butterfield CE, Kraling BM, et al: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886, 2000
188. Brekken RA, Huang X, King SW, et al: Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 58:1952-1959, 1998
189. Ke L, Qu H, Nagy JA, et al: Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor. Eur J Cancer 32A:2467-2473, 1996
190. Millauer B, Shawver LK, Plate KH, et al: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576-579, 1994
191. Gerber HP, Kowalski J, Sherman D, et al: Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60:6253-6258, 2000
192. Ferrara N: Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 56:794-814, 1999
193. Mordenti J, Thomsen K, Licko V, et al: Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol 27:14-21, 1999
194. Mesiano S, Ferrara N, Jaffe RB: Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization. Am J Pathol 153:1249-1256, 1998
195. Borgstrom P, Bourdon MA, Hillan KJ, et al: Neutralizing antivascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 35:1-10, 1998
196. Lee CG, Heijn M, di Tomaso E, et al: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565-5570, 2000
197. Martiny-Baron G, Marme D: VEGF-mediated tumour angiogenesis: A new target for cancer therapy. Curr Opin Biotechnol 6:675-680, 1995
198. Rowe DH, Huang J, Li J, et al: Suppression of primary tumor growth in a mouse model of human neuroblastoma. J Pediatr Surg 35:977-981, 2000
199. Brekken RA, Thorpe PE: VEGF-VEGF receptor complexes as markers of tumor vascular endothelium. J Control Release 74:173-181, 2001
200. Cooke SP, Boxer GM, Lawrence L, et al: A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: Receptor complex. Cancer Res 61:3653-3659, 2001
201. Brekken RA, Overholser JP, Stastny VA, et al: Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 60:5117-5124, 2000
202. Thorpe PE, Ran S: Tumor infarction by targeting tissue factor to tumor vasculature. Cancer J Sci Am 6:S237-S244, 2000 (suppl 3)
203. Benjamin LE, Keshet E: Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A 94:8761-8766, 1997
204. Jain RK, Safabakhsh N, Sckell A, et al: Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 95:10820-10825, 1998
205. Drevs J, Hofmann I, Hugenschmidt H, et al: Effects of PTK787/ZK222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60:4819-4824, 2000
206. Shaheen RM, Davis DW, Liu W, et al: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 59:5412-5416, 1999
207. Wedge SR, Ogilvie DJ, Dukes M, et al: ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 60:970-975, 2000
208. Basu S, Nagy JA, Pal S, et al: The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 7:569-574, 2001
209. Huang X, Molema G, King S, et al: Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275:547-550, 1997
210. Yu JL, Rak JW, Coomber BL, et al: Effect of p53 status on tumor response to antiangiogenic therapy. Science 295:1526-1528, 2002
211. Bevacizumab: Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF. Drugs R D 3:28-30, 2002
212. Chen HX, Gore-Langton RE, Cheson BD: Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology (Huntingt) 15:1017, 1020, 1023-1026, 2001
213. Gorski DH, Beckett MA, Jaskowiak NT, et al: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374-3378, 1999
214. Bergers G, Javaherian K, Lo KM, et al: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808-812, 1999